Latest News

Regenerative medicine spinout OxStem launches subsidiaries to tackle diabetes and inflammation

4th October 2018

All News | Spinouts & Startups

Subsidiaries of the Oxford University spinout, OxStem Immuno and OxStem Beta, will draw on research from the institution.

Oxford University Innovation launches social enterprise support

25th September 2018

All News | Spinouts & Startups

Oxford University Innovation unveils support for impact-driven businesses from academic ideas.

Oxford VR raises £3.2m for development of VR psychological therapies

20th September 2018

All News | Financial News | Spinouts & Startups

The University of Oxford spinout also inks clinical paper in Lancet Psychiatry, appoints CEO and sets up Oxford HQ and London development hub.

Industry veteran appointed as Chief Scientific Officer of OxStem Ltd

10th September 2018

All News | Spinouts & Startups

Dr. Georg C. Terstappen has been appointed to the role of Chief Scientific Officer (CSO) of spinout OxStem Ltd.

Evox Therapeutics secures £35.5m Series B

3rd September 2018

All News | Financial News | Spinouts & Startups

The Oxford University spinout will use the investment to further develop its exosome technology, capable of delivering drugs to previously inaccessible parts of the body.

Celleron Therapeutics enrols patients for clinical trial

20th August 2018

All News | Spinouts & Startups

Celleron Therapeutics, spun out of the University in 2005, has commenced a Phase Ib/II clinical trial investigating drug combination therapy for colorectal cancer.

Oxford University Innovation Q2 2018 Update

1st August 2018

All News | Financial News | Spinouts & Startups

Oxford University spinout external investment nears £1.9bn since 2011 - £506m of which was in the past twelve months.

Oxford University spinout lasers in on diamond security

30th May 2018

All News | Spinouts & Startups

Opsydia, an Oxford University spinout founded last year to create a new level of diamond and gemstone security, officially launches with De Beers deal.